ARDS associated acute brain injury: from the lung to the brain

Mairi Ziaka and Aristomenis Exadaktylos

Abstract
A complex interrelation between lung and brain in patients with acute lung injury (ALI) has been established by experimental and clinical studies during the last decades. Although, acute brain injury represents one of the most common insufficiencies in patients with ALI and acute respiratory distress syndrome (ARDS), the underlying pathophysiology of the observed crosstalk remains poorly understood due to its complexity. Specifically, it involves numerous pathophysiological parameters such as hypoxemia, neurological adverse events of lung protective ventilation, hypotension, disruption of the BBB, and neuroinflammation in such a manner that the brain of ARDS patients—especially hippocampus—becomes very vulnerable to develop secondary lung-mediated acute brain injury. A protective ventilator strategy could reduce or even minimize further systemic release of inflammatory mediators and thus maintain brain homeostasis. On the other hand, mechanical ventilation with low tidal volumes may lead to self-inflicted lung injury, hypercapnia and subsequent cerebral vasodilatation, increased cerebral blood flow, and intracranial hypertension. Therefore, by describing the pathophysiology of ARDS-associated acute brain injury we aim to highlight and discuss the possible influence of mechanical ventilation on ALI-associated acute brain injury.

Keywords: Acute brain injury, Acute respiratory distress syndrome, Acute lung injury, Brain–lung interactions, Hypoxemia, Blood–brain barrier disruption, Inflammation, Mechanical ventilation

Introduction
Despite the remarkable advances in the management of acute lung injury (ALI) and acute respiratory syndrome (ARDS), ALI remains a relatively common and highly morbid or lethal condition [1]. ARDS-associated brain dysfunction is one of the most common complications in critically ill ARDS patients and represents one of the most frequent organ insufficiencies, often persisting months after hospital discharge [2]. Although the pathogenesis of ARDS associated brain injury is still not fully understood, it is well established that lung and brain represent an integrated ensemble [3], which interacts strongly through complex pathophysiological pathways [4]. Various factors have been suggested to contribute to the pathogenesis of ARDS-associated brain injury, including hypoxemia, neurological adverse events of lung protective ventilation, hypotension, disruption of the blood–brain barrier (BBB), and altered neurotransmission. Three main mechanisms seem to be involved to its manifestation, that is, inflammation, hypoxemia, and adverse events of mechanical ventilation [4–7]. Recognition and understanding of the pathophysiological mechanisms associated with ARDS encephalopathy might lead to improved clinical outcomes and therapeutic implications. The present review aims to analyze the various clinical central nervous system presentations in patients with ARDS. Moreover, we sought to describe the pathophysiology of neurologic manifestations, which occur secondary to ALI from a mechanistic standpoint. More specifically, we discuss the pathophysiological issues related to lung–brain interactions and provide an updated overview regarding the role of inflammation,
hypoxemia, and haemodynamics on the development of ARDS-associated secondary brain injury. Finally, the impact of mechanical ventilation (MV) on the pathogenesis of acute brain injury in ARDS patients without pre-existing brain injury is also analyzed.

**Clinical CNS presentations in ARDS patients**

Traditionally, refractory respiratory failure has been considered a relatively rare cause of death in patients with ARDS, occurring in about 20% of the patients [8–10], while studies report irreversible respiratory insufficiency in only 16% of ARDS patients [8]. However, the classical study of Ferring et al. [10] with 129 ARDS patients demonstrated sepsis, that is, multi-organ failure (MOF), as the primary mortality cause in 49% of ARDS patients, followed by respiratory failure (16%), cardiac dysfunction (15%), severe neurological injury (10%), and other causes (8%) (Fig. 1) [10]. ARDS is an acute inflammatory condition characterized by the release of pro-inflammatory mediators into the systemic circulation. The most important pro-inflammatory mediator are interleukin (IL)-6, IL-1β, IL-8 and tumor necrosis factor (TNF)-α, leading potentially to dysfunction of distant organs and systems [11–13]. The central nervous system appears to be one of the most targeted organs and systems [2]. Indeed, a study by Hoppkins and co-authors testing the assumption that ARDS may cause hypoxemia-induced brain injury found that all ARDS survivors (i.e., 100% of the cases) manifested cognitive and affective impairments at discharge. Interestingly, even 1 year after ARDS was observed, almost 80% of the patients still suffered from at least one neurocognitive alteration (i.e., impaired memory, attention, concentration, and/or mental processing speed) [14]. This first evidence were further supported by clinical and experimental studies showing that patients with ARDS seem to be at increased risk for developing Intensive Care Unit [15] delirium, independent of MV. Moreover, the majority of this group of patients appears to develop new cognitive, functional, and physical impairments with long-term consequences in their quality of life [16–20]. Recently, studies tracking the impact of coronavirus-2 (SARS-CoV-2) outbreak on critically ill patients described the emergence of a variety of neuropsychiatric features, such as encephalopathy, agitation, confusion, inattention, disorientation, and poorly organized movements in critically ill SARS-CoV-2 patients with severe acute respiratory failure [21–23].

Risk factors for the significant increase of the emergence of delirium include advanced age, preexisting neurocognitive disorders, history of alcohol abuse, severe systemic disease (e.g., sepsis and diseases of the respiratory tract), metabolic abnormalities, inadequate pain management, mechanical ventilation, surgery, and drugs [24]. Classic pharmaceutical
agents implicated in the development of neurocognitive dysfunction include benzodiazepines, steroids, long-acting opioids, and anticholinergic medications, highlighting their use with great caution in elderly patients [25, 26]. Moreover, sedation and analgesia are frequently used to control anxiety and motoric unrest, pain and agitation, autonomic disability avoidance, brain metabolism reduction, and MV optimization [27, 28]. Furthermore, light rather than deep sedation and brief cessation of sedation for daily wake-up tests are recommended for reducing the risk of neurocognitive dysfunction, duration of MV, and hospital stay based on facts which show that depth of sedation may trigger the development of delirium [20, 26, 29–33].

ICU delirium is multifactorial with its pathophysiology comprising the influence of the underlying illness (e.g., sepsis, trauma, etc.), neuroinflammation, cerebral hypoperfusion from hypoxemia, breakdown of the BBB, disruptions of cerebral blood flow (CBF), and endothelial dysfunction [34]. On the other hand, however, critically ill patients have an additional contribution from MV; MV despite being lifesaving could as a side-effect exacerbate pulmonary and systemic inflammation and, hence, lead to lung and distant organ injury [4, 34]. In fact, it has been shown that critically ill patients are commonly admitted to the ICUs for MV [35]. Patient-ventilator interactions and the likelihood for developing acute lung injury is largely determined by the neural control of ventilation and the immune response, which could make patients susceptible to develop short- and long-term neuropsychological impairments, including delirium, sleep disturbances, persistent cognitive impairment, and post-traumatic stress disorder [36]. Although the interactions of the mechanically ventilated lung and CNS are complex and discussed in detail in the Pathophysiology Section, experimental and clinical studies suggest the existence of an interacting signalling. This interacting signalling could be due to a physiological mechanism, as for example the Hering–Breuer reflex. Another possible cause could be a pathological process, such as excessive alveolar stretch and over-distension, which could lead to maladaptive responses and contribute to the observed neurocognitive impairments and psychological alterations [36, 37].

Given that ICU delirium prolongs hospitalisation duration of mechanical ventilation patients and, ultimately, increases mortality [20, 30–32] emphasis should be given on prevention strategies and possible interventions, involving early identification of risk factors, on-time recognition of latent neurocognitive symptoms, avoidance of triggering factors, and multifactorial patient approach.

Pathophysiology of ARDS-associated brain dysfunction

The role of inflammation

More than two decades ago, Slutsky and Tremplay tried to explore the hypothesis of the contribution of lung injury and mechanical ventilation in the initiation of systemic inflammatory responses, which could lead to multiple systemic organ failure [38]. After their publication in 1997, an increasing body of evidence suggests that acute lung injuries and mechanical ventilation could elicit release of inflammatory mediators into the systemic circulation, creating a pro-inflammatory environment with potential detrimental effects on distal organs including the brain [39, 40]. The theory of systemic inflammatory reaction with subsequent deleterious effects on distant organs is further supported by anatomical and functional components. The pulmonary vasculature hosts up to one third of all neutrophils outside the bone marrow; as it receives the entire cardiac output, there is a significant potential for interaction with circulating neutrophils [38]. In addition, disruption of the lung microvascular barrier due to increased endothelial and epithelial permeability and alveolar injury due to high levels of pro-inflammatory cytokines allow efflux of inflammatory mediators into the systemic circulation [41].

Moreover, common causes of acute lung injury such as trauma, infections, or surgery not only affect the lungs but also generate further systemic inflammation and organ dysfunction through dysregulated production of inflammatory mediators, excessive endothelial dysfunction, alterations of the blood–brain barrier (BBB), neuroinflammation, and neuroglial cell death [42, 43]. Cytokines such as IL-1β and TNF-α are central mediators of neurogeneration [44, 45] suggesting a potential link between acute lung injury and development of brain dysfunction. Indeed, cytokines (e.g., TNF-α, IL-1α, IL-1β and IL-6) can directly cause neuronal apoptosis and produce a stereotyped cluster of nonspecific signs such as impaired concentration, anorexia, fatigue, diminished motivation, depression, and anorexia [46].

Interestingly, at the molecular level, hippocampus, which is involved in memory and learning processes, has a high density of IL-1 receptors, which could explain the common occurrences of hippocampal injuries in patients with acute lung injury regardless of the degree of hypoxia [47–49]. Experimental models of ARDS found a significant increase in S-100b protein levels—a plasmatic marker of brain injury—compared to hypoxic animals without ARDS [50]. Moreover, hippocampal damage occurred only in individuals with ARDS. Fries et al. concluded that for the same degree of hypoxemia, acute lung injury results to stronger brain injury when compared to hypoxemia induced
by reducing the inspired oxygen fraction [50]. This suggestion is in accordance with the study of Nguyen et al. [51], who reported that elevated concentrations of S-100b and neuron-specific enolase (NSE) are frequently associated with brain injury in patients with severe sepsis and septic shock [51]. This pathogenetic mechanism is further supported by an experimental study in pigs with ARDS and intracranial hypertension, in which it was found that their combination induced damage in the hippocampus and decreased density in brain CT due to hypoxia-associated cerebral oedema, indicating synergistic exacerbation of pre-existing brain damage [52].

**Effects of inflammation in blood–brain barrier**

The vascular BBB is an important neurobiological structure with a highly regulated interface between the blood and the brain [53]. It responds to signals of the immune system and regulates the neuroimmune communication of compartments of the blood and the brain [54]. However, during prolonged central nervous system inflammation [7] and systemic inflammatory response, a variety of soluble inflammatory mediators may influence the integrity of BBB and the subsequent neurological outcomes of the patients [53, 55]. Peripheral cytokine elevation activates supraphysiological responses, which alter the BBB, including increased solute permeability and lymphocyte trafficking, activation of endothelial cells, impairment of systemic and cerebral blood flow, and alterations of glucose metabolism in the brain [53, 56].

Experimental studies suggest that microglial cell activation plays a fundamental role in the development of BBB alterations [57, 58]. It has been also reported that enhanced peripheral cytokines induce a massive biochemical cascade that activates intracranial located microglia, the resident brain macrophages, to produce pro-inflammatory cytokines to recruit monocytes to the brain, leading ultimately to neuronal apoptosis and cerebral oedema [4, 59–61].

In addition, activation of the microvascular endothelial cells due to the binding of peripheral cytokines to the endothelium of vascular BBB alters adhesion and permeability and results to active cytokine transport between blood and brain compartments [61–63]. Indeed, elevated cytokines have been described in the CSF of critically ill patients, indicating disruption of the BBB and neuroinflammation [54, 64], findings further supported by recent studies in SARS-CoV-2 patients with neurological presentation [65–67]. Accordingly, previous clinical and experimental studies describe elevated plasma levels of S-100b and NSE, indicating BBB dysfunction, astrocyte and neuronal injury [37, 50, 51].

**Inflammation and mechanical ventilation**

Mechanical ventilation is often a crucial life-support tool in the resuscitation of patients with acute lung injury and ARDS [68, 69]. However, mechanical ventilation per se can induce brain damage either by inducing an excessive release of pro-inflammatory cytokines (e.g., IL-1β, IL-6 and TNF-α) or by changing the vagal signal leading to neuroinflammation and neuronal death [37, 50, 68, 70–74]. Interestingly, an increased amount of evidence suggests that even a short period of mechanical ventilation may dramatically increase hippocampal and plasma levels of IL-1β, IL-6 and TNF-α [71]. This proposal is further supported by a recent experimental study of Sparrow and colleagues, who reported that acute lung injury due to mechanical ventilation induced reversible neuronal injury and inflammation in the frontal cortex and hippocampus of mechanically ventilated mice. Importantly, inhibition of IL-6 signalling reduced frontal and hippocampal apoptosis [75].

Clinical and experimental evidence have shown that the ventilator strategy may activate or even propagate the systemic inflammatory response, leading to dysfunction of multiple organs and systems, including the brain [38, 73]. Over the past 20 years, numerous studies have demonstrated a biological response with release of a variety of pro-inflammatory mediators and local initiation of inflammatory processes induced by an injurious ventilator strategy [69], which can potentially cause local lung injury. In addition, distal organs are also affected due to decompartmentalization of local inflammation to translocation into the systemic circulation [69]. The fact, that mechanical ventilation strategy using high tidal volumes may enhance the release of mediators such as IL-1β, IL-6 and TNF-α, is well recognized [76, 77]. Specifically, for the lung–brain crosstalk, it has been proposed that mechanical ventilation may propagate regional brain activation. For example, the experimental study of Quilez et al. showed that MV with high tidal volumes can cause more c-fos brain expression, a marker of brain activation, in healthy rats compared to protective mechanical ventilation, supporting the iatrogenous enhancement of neuroinflammation [74].

Although the mechanisms through which lung damage can reach the central nervous system are still poorly understood [74], the pivotal role of mechanotransduction (i.e., the conversion of mechanical stimuli into biological signals by mechanoreceptors) in this crosstalk has been proposed [76, 78]. Nowadays, it is also recognized that pro-inflammatory mediators can reach key structures in the brain via circumventricular organs and activate the autonomous nervous system in the periphery [79].

Hence, the occurrence of a lung–brain interplay through different mechanisms and biochemical pathways
underlines the need for greater control of modified variables, as for example mechanical ventilation in the maintenance of lung and brain homeostasis.

The role of hypoxemia

The brain is a highly metabolic and oxidative organ accounting about 20% of the basal oxygen budget, despite its small size, which represents about 2% of body weight [80]. Therefore, the brain is vulnerable to hypoxic conditions [81]. Indeed, hypoxia has been incriminated for causing tissue hypoxia and for increasing the risk of multiple organ failure including the brain [82]. However, although a number of studies have shown various pathogenetic effects of hypoxemia on the brain function of patients with severe respiratory insufficiency, it still remains unclear, if hypoxemia is a contributing cause for the emergence of cognitive dysfunction [81, 82]. Until now, it is well established that hypoxic stimuli can compansatory increase cerebral brain flow via cerebral vasodilation in order cerebral oxygen delivery to be maintained [81]. In addition, tissue oxygenation is regulated from various parameters, as for example dissolved oxygen, haemoglobin concentration, cardiac function, pH, and body temperature [81, 82]. In a clinical study of mechanically ventilated ALI-survivors, Mikkelsen et al. found that a mean PaO2 of 72 mmHg was significantly associated with long-term cognitive dysfunction in comparison to a mean PaO2 of 87 mmHg [83]. However, it should be kept in mind that hypoxic stimuli activate peripheral chemoreceptors, which could in turn lead to hyperventilation, subsequent hypocapnia and cerebral vasoconstriction, and reduced cerebral perfusion [84].

Cerebral microbleeds are small, hypodense lesions with a maximum size of up to 10 mm on haemorrhage sensitive MRI sequences. Although their causal association with chronic hypertension, cerebral amyloid angiopathy, and diffuse axonal injury is well documented, it has been recently noted that they may be causally related to less identifiable originators, such as sepsis and ARDS [85]. Riech and colleagues described in 2015 multiple microhaemorrhages, predominantly in the splenium of the corpus callosum, on the MRI of three patients who survived ARDS, findings that are typically seen in patients with high-altitude lesions, raising the question of common pathogenetic mechanisms between the two disease entities [86]. More recently, similar findings were presented by Fanou et al. in 12 patients with respiratory failure, of whom 11 received mechanical ventilatory support and 3 were on extra-corpooreal circulation. More specifically, the authors described haemorrhagic microlesions, diffusely involving the juxtacortical white matter and corpus callosum but sparing the cortex, deep and periventricular white matter, basal ganglia, and thalami [87]. These findings seem to be confirmed by more recent studies in patients affected with severe SARS-CoV-2-infection. Indeed, a recent meta-analysis showed that these patients exhibit much less deep microbleeds or lobular microbleeds, findings that are typically seen in patients with hypertensive angiopathy and cerebral amyloid angiopathy. In these patients a heterogeneous pattern of cerebral haemorrhagic manifestations is described, such as diffuse cerebral microhaemorrhages, affecting deep cortical white matter structures, including the corpus callosum as well as the brainstem and the cerebellum [88]. Although haemorrhagic manifestations are reported as relatively frequent complications in patients with ARDS (25%) [5], the exact pathogenetic mechanism for their occurrence still remains unclear. One hypothesis states that hypoxemia and inflammation could lead to endothelial and BBB dysfunction and, additionally, to extravasation of erythrocytes, resulting to diffuse cerebral microbleedings [87]—a phenotype of small vessel disease—which may further evolve to haemorrhagic stroke [5].

Ischaemic brain injury is another type of injury commonly observed in patients with acute lung injury. Its pathophysiologic mechanisms include activation of the endothelial cells and systemic inflammation, which result to subsequent activation of the coagulation system and to thrombi formation. Increased risk of ischaemic stroke is additionally associated to reactive oxygen radicals due to acute lung injury and hypoxemia [89], while prolonged hypoxemia in patients with severe respiratory failure leads to reduced delivery of oxygen and glucose to the brain. As a consequence mitochondrial dysfunction and upregulation of energy-dependent ion chains are manifested, causing neuronal apoptosis, necrosis, and cytotoxic oedema [5, 6]. This observation is of high importance especially in reference to structures, which are more sensitive to diffuse ischaemic injury due to their high metabolic demands (e.g., hippocampus and grey matter structures) [90] and in accordance with the study of Janz et al., who reported that hypoxic brain injury in patients with ARDS was most commonly observed in the pyramidal neurons in the CA1 region of the hippocampus [49]. The pathophysiologial mechanisms through which acute hypoxia results to hippocampal injury include glycolysis, increase of adenosine concentrations, cardiopulmonary compensatory response, oxidative stress, and mitochondrial disruption. These mechanisms end up ultimately to decreased synaptic plasticity, neuronal necrosis, and inhibition of long-term potentiation [91].

Furthermore, hypoxemia has been incriminated for the development of cerebral oedema and diffuse cerebral
atrophic, although it still remains unclear, if the underlying responsible pathogenetic mechanism is hypoxemia or inflammation [5, 6].

Finally, it is demonstrated that erythropoietin [92], which is endogenous expressed in the CNS, is capable to induce neuroprotective properties in vivo and in vitro. EPO and EPO receptors are expressed in various brain regions and hypoxic/ischaemic insults predominantly stimulate their expression [93–99]. EPO- signalling plays a pivotal role in adult neurogenesis and neuroblast migration to ischaemic regions in vivo, besides its direct protection of neurons and modulation of the angiogenic response. It has been also shown that EPO expression is mainly restricted to some cellular types, predominantly astrocytes, but also neurons [93, 100, 101]. In addition, the hypoxia inducible factor [102]—a heterodimer of HIF-α and HIF-β subunits—has been found to regulate hypoxia-induced stimulation of EPO expression. In more detail, oxygen levels are effective inducers of the HIF-α subunit expression, whereas the expression of the HIF-β subunit is constitutive and dimerises with transcription factors. Interestingly, a key study examined the role of HIF-1α and HIF-2α (i.e., two of the three HIF-α subunits) in the generation of paracrine protective signals by astrocytes, which modulate the survival of neurons exposed to oxygen–glucose deprivation. The study showed that HIF-2α is the main regulator of EPO expression in astrocytes during hypoxia, indicating that astrocytes play an important neuroprotective role during hypoxia/ischaemia [103].

**Mechanical ventilation**

As mentioned above, although mechanical ventilation is a life-saving therapeutic intervention in the management of critically ill patients, it is well documented that it can trigger or exacerbate pulmonary and systemic inflammation [104, 105]. The underlying pathogenetic mechanisms include overstretching, recurrent alveolar collapse, and re-expansion during each respiratory cycle [106]. In addition, it appears that the conversion of mechanical to biological stimuli is involved in the pathophysiology of ventilator-associated lung injury [107] with deleterious effects both locally on the lung level and on distant organs and systems including the central nervous system [4, 108]. Multiple mechanisms, including neuroendocrine, inflammatory, hormonal and neural pathways, appear to be involved in mechanical ventilation-related brain damage [4, 105, 109]. In addition, it has been shown that an imbalance in neurotransmitters (i.e., dopamine and acetylcholine) contributes to the development of cognitive dysfunction in critically ill ICU patients [2, 49, 110, 111]. Previous research demonstrates that mechanical ventilation alters the vagal signal, leading to neuroinflammation and neuronal death (Fig. 2) [50, 70–74, 112–114]. Indeed, numerous studies have documented an increase in the concentration of inflammatory cells in the hippocampus mediated by the vagus nerve, affecting postoperative memory in experimental mouse models [71, 115]. The hypothesis of vagus nerve mediation in the induction of cerebral inflammatory response seems to be further supported by the finding that performing bilateral vagotomy prior to mechanical ventilation in mice protects against the development of brain damage [70]. In addition, several preclinical studies concluded that patients, who were mechanically ventilated for prolonged periods of time, showed deteriorated cognitive functions compared to patients, who were not mechanically ventilated, or patients, who received mechanical ventilation for a short period of time [71, 112, 113]. Furthermore, increased concentrations of inflammatory cells and proapoptotic proteins have been reported in the brains of patients receiving mechanical ventilation support [50, 70–74, 112–114]. Moreover, it appears that patients who received higher tidal volumes have more intense hippocampal activity, as shown using functional MRI, resulting in greater tissue damage than patients mechanically ventilated with lower tidal volumes [70]. Finally, it has been shown that higher tidal volumes may result in abnormal neuronal activity in the retrosplenial cortex and thalamus, as evidenced by higher c-Fos concentrations in these brain regions, compared to lower tidal volumes [74].

It is well documented that protective mechanical ventilation with low tidal volume and positive end-expiratory pressure (PEEP) in patients with ARDS improves outcome by reducing lung strain and preventing inflammation [4, 78]. However, it should be taken additionally into account that a protective ventilator strategy may lead to self-inflicted lung injury, hypercapnia and subsequent cerebral vasodilatation, increased cerebral blood flow, and intracranial hypertension [116]. Nevertheless, the harmful of permissive hypercapnia was investigated in a small study of 12 patients with subarachnoid haemorrhage undergoing protective mechanical ventilation. The authors reported that mechanical ventilation with tidal volume of 5–8 ml/kg and moderate levels of PEEP led to PaCO2 levels of 50–60 mmHg without negatively affecting intracerebral pressure [117]. Moreover, clinical and experimental studies have shown that ventilation with high tidal volumes induces higher hippocampal activation associated with more tissue injury and a pathological neuronal activity, suggesting an iatrogenic effect of high tidal volume ventilation on the brain [68].

High PEEP is another part of the protective ventilation strategy used in ARDS to prevent alveolar collapse, recruit alveoli, and reduce atelectrauma [4, 118].
Yet, PEEP may also increase intracranial pressure (ICP), reduce cerebral venous return, and cerebrospinal fluid outflow [4, 119]. The underlying pathophysiologic mechanisms are complex and involve many factors among them cerebral vasodilatation due to elevated intrathoracic pressures and reduced mean arterial pressure [4, 119]. On the other hand, it has been suggested that PEEP increases ICP, only when PEEP causes alveolar hyperinflation, although when PEEP causes alveolar recruitment, there is no influence on cerebral perfusion and ICP [120].

Given the adverse effects of mechanical ventilation (e.g., the release of local and systemic inflammatory response, the often required deep sedation and the neuromuscular blockade and immobility), the alternative of avoiding it seems increasingly interesting [121]. Despite controversial and conflicting views, non-invasive ventilation (NIV) can be considered for the initial support of patients with ARDS [122, 123]. Indeed, the LUNG SAFE study showed that 15.5% of patients with ARDS initially underwent non-invasive mechanical ventilation. However, these patients were found to have lower PEEP levels and higher respiratory volumes and respiratory rates than patients receiving invasive mechanical ventilation. In addition, the use of NIV was associated with greater mask leaks, patients’ intolerance, and gastric distension [124]. In addition, it appears that the probability of failure of NIV increases significantly with the severity of ARDS [124], while at the same time this failure worsens the outcome [125], suggesting that delays in intubation can have devastating effects. On the other hand, it appears that the use of NIV as an initial approach in patients with ARDS is associated with avoidance of intubation in half of the patients and, thus, with a lower incidence of ventilator-associated pneumonia and related mortality [122, 126]. Due to conflicting evidence from existing clinical studies and the lack of well-documented recommendations for or against the use of NIV in severely affected patients with ARDS [127], its use should be limited to strictly selected patients. Further high quality research is needed to clearly define the role of NIV in the treatment of critically ill patients with ARDS.

**Haemodynamic compromise**

Haemodynamic instability is a leading cause of increased mortality in patients with ARDS and is frequently associated with cor-pulmonale, deleterious effects of MV on the right ventricular function and the pulmonary vascular mechanics, being additionally related to sepsis [128, 129]. Specifically, mechanical ventilation causes changes in lung volume and, consequently, alters the vascular...
tone and the pulmonary vascular resistance. Especially when high tidal volumes are used, mechanical ventilation may lead to cardiac–tamponade similar phenomenon by compressing the heart in the cardiac fossa [130]. Moreover, changes in transpulmonary pressure influences right ventricular afterload, whereas alterations in pleural pressure affect venous return, leading to haemodynamic compromise [128].

Because the brain is an intensive metabolic organ, accounting for about 20% of the total body’s consumption of oxygen [131, 132] under normal conditions, CBF is approximately 50 ml/min/100 g of brain tissue and remains constant, if mean systemic arterial pressure ranges between 60 and 150 mmHg, ensuring brain's autoregulation [133–135]. Following this reasoning, it may be concluded that haemodynamic instability in mechanically ventilated patients with ARDS impairs CNS homeostatic mechanisms, making the brain vulnerable to the development of secondary injury [128, 129, 136, 137].

A growing body of evidence supports the hypothesis that haemodynamic alterations, resulting to cerebral hypoperfusion, play a fundamental role in the development of neurocognitive dysfunction in critically ill patients [138, 139]. Experimental and clinical studies have shown that brain hypoperfusion is clearly associated with metabolic and energetic dysregulation, degeneration of brain capillaries, loss of cholinergic receptors, disruption of protein synthesis, and neuronal damage, affecting specific brain regions sensitive to the above mentioned processes and, predominantly, the hippocampus [91, 140, 141]. However and especially in patients with septic shock, microcirculatory changes along with macrocirculatory changes, may impair neurovascular uncoupling, disrupt the BBB, and activate the coagulation cascade, leading to further ischaemic damages [142].

Although outside of the scopes of the current review, it should be emphasized that cerebrovascular heterogeneity should not be neglected. Significant regional, cellular, and functional differences exist and should be taken into account with specific cerebrovascular regions being differentially implicated in the pathophysiology of various neurological processes [9, 11, 143–145].

Conclusions
To conclude, experimental and clinical studies strongly suggest a perceptible and complex crosstalk between the lung and the brain in patients with acute lung injury. The aim of the current review was to focus on the pathophysiology of acute brain injury in patients with ALI/ARDS. As we have shown, ARDS involves activation of systemic inflammatory cascades and neuroinflammation, so that the brain of ARDS patients and, especially, the hippocampus becomes very vulnerable to the development of secondary lung-mediated acute brain injury. A protective ventilator strategy could reduce or even minimize further systemic release of inflammatory mediators and, thus, maintain brain homeostasis. Further refinements are needed to enhance our understanding of ARDS associated acute brain injury and evaluate optimal management of lung-associated acute brain injury.

Acknowledgements
Figures created with BioRender.com.

Author contributions
The study was designed by MZ and AE. MZ searched the articles and drafted the manuscript, to which AE contributed and helped to revise. Both authors read and approved the final manuscript.

Funding
Publication costs for this article were funded by the authors’ institutions.

Availability of data and materials
Not applicable.

Declarations
Ethical approval and Consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Internal Medicine, Thun General Hospital, Thun, Switzerland
2. Department of Emergency Medicine, Inselspital, University Hospital, University of Bern, Bern, Switzerland.

Received: 19 January 2022   Accepted: 29 July 2022
Published online: 13 August 2022

References
1. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syn-
drome. N Engl J Med. 2017;377(6):562–72.
2. Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care. 2019;23(1):352.
3. Stevens RD, Puybasset L. The brain-lung-brain axis. Intensive Care Med. 2011;37(7):1054–6.
4. Ziaka M, Exadaktylos A. Brain-lung interactions and mechanical ventil-
ation in patients with isolated brain injury. Crit Care. 2021;25(1):358.
5. Huang M, et al. Pathophysiology of brain injury and neurological outcome in acute respiratory distress syndrome: a scoping review of preclinical to clinical studies. Neurocrit Care. 2021;35(2):S18–27.
6. Huang FP, et al. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol. 1998;28(12):4062–70.
7. Brain Trauma F, et al. Guidelines for the management of severe traumatic brain injury. XIV Hyperventilation J Neurotrauma. 2007;24(Suppl 1):S87-90.
8. Montgomery AB, et al. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1985;132(3):485–9.
9. Estenssoro E, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med. 2002;30(1):2450–6.
10. Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory failure? Eur Respir J. 1997;10(6):1297–300.

11. Ranieri VM, et al. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA. 2000;284(1):43–4. https://doi.org/10.1001/jama.284.1.43.

12. Husain-Syed F, Slutsky AS, Ronco C. Lung-Kidney cross-talk in the critically ill patient. Am J Respir Crit Care Med. 2016;194(4):402–14. https://doi.org/10.1164/rccm.201511-2121SS.

13. Klein SJ, et al. Interactions between lung and kidney in the critically ill. Kidney Int. 2013;84(4):354–61. https://doi.org/10.1038/ki.2013.157.

14. Hopkins RO, et al. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160(1):150–6.

15. Elmer J, et al. Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*. Crit Care Med. 2013;41(8):1992–2001.

16. Hsieh SJ, et al. The association between acute respiratory distress syndrome, delirium, and in-hospital mortality in intensive care unit patients. Am J Respir Crit Care Med. 2015;191(1):71–8.

17. Hopkins RO, Brett S. Chronic neurocognitive effects of critical illness. Curr Opin Crit Care. 2005;11(4):369–75.

18. Hopkins RO, et al. Risk factors for depression and anxiety in survivors of acute respiratory distress syndrome. Gen Hosp Psychiatry. 2010;32(2):147–55.

19. Bienvenu OJ, et al. Depressive symptoms and impaired physical function after acute lung injury: a 2-year longitudinal study. Am J Respir Crit Care Med. 2012;185(5):517–24.

20. Ely EW, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286(21):2703–10.

21. Battaglini D, et al. Brain-heart interaction after acute ischemic stroke. Curr Opin Crit Care. 2020;26(4):1163.

22. Battaglini D, et al. Neurological complications and noninvasive multimodal neuromonitoring in critically ill mechanically ventilated COVID-19 patients. Front Neurol. 2020;11:602114.

23. Helms J, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268–70.

24. Hayhurst CJ, Pandharipande PP, Hughes CG. Intensive care unit delirium: a review of diagnosis, prevention, and treatment. Anesthesiology. 2016;125(6):1229–41.

25. Kofidis K, Marra A, Ely EW. ICU delirium - a diagnostic and therapeutic challenge in the intensive care unit. Anaesthesiol Intensiv Ther. 2018;50(2):160–7.

26. Pandharipande PP, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–53.

27. Oddo M, et al. Optimizing sedation in patients with acute brain injury. Crit Care. 2016;20(1):128.

28. Opdenakker G, et al. Sedatives in neurocritical care: an update on pharmacological agents and modes of sedation. Curr Opin Crit Care. 2019;25(2):97–104.

29. Riker RR, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489–99.

30. Ely EW, et al. Delirium as a predictor of mortality in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2009;301(5):489–99.

31. Vincent JL, et al. Comfort and patient-centred care without excessive pharmacological agents and modes of sedation. Curr Opin Crit Care. 2020;26(2):1163.

32. Jaecklin T, Otulakowski G, Kavanagh BP. Do soluble mediators cause brain damage? J Neuroinflammation. 2016;13(1):15.

33. Esteban A, et al. Evolution of mortality over time in patients receiving mechanical ventilation. Am J Respir Crit Care Med. 2013;188(2):200–30.

34. Albaiceta GM, et al. The central nervous system during lung injury and mechanical ventilation: a narrative review. Br J Anaesth. 2021;127(4):648–59.

35. Lopez-Aguilar J, et al. Lung-brain interaction in the mechanically ventilated patient. Med Intensiva. 2013;37(7):485–92.

36. Slutsky AS, Tremblay LN. Multiple system organ failure is mechanical ventilation a contributing factor? Am J Respir Crit Care Med. 1998;157(6 Pt 1):1722–5.

37. Hegeman MA, et al. Ventilator-induced endothelial activation and inflammation in the lung and distal organs. Crit Care. 2009;13(6):R182.

38. Khadaroo RG, Marshall JC. ARDS and the multiple organ dysfunction syndrome Common mechanisms of a common systemic process. Crit Care. 2002;18(1):127–41.

39. Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2019;40(1):31–9.

40. Simard AR, Rivest S. Do pathogen exposure and innate immunity cause brain diseases? Neurol Res. 2005;27(7):717–25.

41. Turpin NR, Rivest S. Unraveling the molecular details involved in the intimate link between the immune and neuroendocrine systems. Exp Biol Med (Maywood). 2004;229(10):1096–1006.

42. Pustovtseva A, Stevens RD. Mechanisms of neurologic failure in critical illness. Crit Care Clin. 2008;24(1):1–24.

43. Allan SM, Tyrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Neurosci. 2005;5(8):629–40.

44. Danzter R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222–34.

45. Parmet P, et al. Expression and regulation of interleukin-1 receptors in the brain Role in cytokines-induced sickness behavior. J Neuroimmunol. 2002;125(1–2):5–14.

46. Neves G, Cooke SF, Bliss TV. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci. 2008;9(1):65–75.

47. Jand DR, et al. Brain autopsy findings in intensive care unit patients previously suffering from delirium: a pilot study. J Crit Care. 2010;25(3):538.

48. Fries M, et al. S-100 protein and neurohistopathologic changes in a porcine model of acute lung injury. Anesthesiology. 2005;102(4):761–7.

49. Nguyen DN, et al. Elevated serum levels of S100beta protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med. 2006;34(7):1967–74.

50. Heuer JF, et al. Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs. Intensive Care Med. 2011;37(7):1182–91.

51. Galea I. The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18(11):2489–501.

52. Ercksson MA, et al. Interactions of SARS-CoV-2 with the Blood-Brain Barrier. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22052681.

53. Alquiasis-Burgos I, et al. Neurological complications associated with the blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection. Mol Neurobiol. 2021;58(2):520–35.

54. Sonnevile R, et al. Understanding brain dysfunction in sepsis. Ann Intensive Care. 2013;3(1):15.

55. Yenari MA, et al. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006;37(4):1087–93.

56. Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43(4):348–64.

57. Alexander JJ, et al. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int. 2008;52(3):447–56.

58. D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci. 2009;29(7):2089–102.

59. Cerqueira J, et al. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119(6):737–54.

60. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to peripheral organ inflammation. J Neurosci. 2009;29(7):2089–102.

61. Cerejeira J, et al. The neuroinflammatory hypothesis of delirium. Acta Neurochem. 2010;57(6):1558–567.

62. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to peripheral organ inflammation. J Neurosci. 2009;29(7):2089–102.
66. Pilotto A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021;73(9):e3019–26.
67. Garcia MA, et al. Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation. medRxiv. 2021. https://doi.org/10.1101/2021.01.10.20249014.
68. Bassi TG, Rohrs EC, Reynolds SC. Systematic review of cognitive impairment and brain insult after mechanical ventilation. Crit Care. 2021;25(1):199.
69. Curley GF, et al. Biotrauma and ventilator-induced lung injury: clinical implications. Chest. 2016;150(5):1109–17.
70. Gonzalez-Lopez A, et al. Lung purinoceptor activation triggers ventilator-induced brain injury. Crit Care Med. 2019;47(11):e911–8.
71. Chen C, et al. Prolonged mechanical ventilation-induced neuroinflammation affects postoperative memory dysfunction in surgical mice. Crit Care. 2015;19:159.
72. Kamuf J, et al. Lung injury does not aggravate mechanical ventilation-induced early cerebral inflammation or apoptosis in an animal model. PLoS ONE. 2018;13(8):e0202311.
73. Bickenbach J, et al. Neurological outcome after experimental lung injury. Respir Physiol Neurobiol. 2011;179(2–3):174–80.
74. Quilez ME, et al. Injurious mechanical ventilation affects neuronal activation in ventilated rats. Crit Care. 2011;15(3):R124.
75. Sparrow NA, et al. IL-6 inhibition reduces neuronal injury in a murine model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2021;65(4):403–12.
76. Crimi E, Stutsky AS. Inflammation and the acute respiratory distress syndrome. Best Pract Res Clin Anaesthesiol. 2004;18(3):477–92.
77. Ziaka A, et al. High-tidal-volume mechanical ventilation and lung inflammation in intensive care patients with normal lungs. Am J Crit Care. 2020;29(1):15–21.
78. Mazzeo AT, Fanelli V, Mascia L. Brain-lung crosstalk in critical care: how protective mechanical ventilation can affect the brain homeostasis. Minerva Anestesiol. 2013;79(3):299–309.
79. Akroot N, Sharshar T, Annane D. Mechanisms of brain signaling during sepsis. Curr Neuropsychopharmacol. 2005;4(4):296–301.
80. Grubb RL Jr, et al. The effects of changes in PaCO2 on cerebral blood flow, blood flow, and vascular mean transit time. Stroke. 1974;5(5):630–9.
81. Holland RL, et al. Hypoxemia, oxygen content, and the regulation of cerebral blood flow. Am J Physiol Regul Integr Comp Physiol. 2016;310(5):R598–413.
82. Holzgrafe B, et al. Does permissive hypoxaemia during extracorporeal membrane oxygenation cause long-term neurological impairment? a study in patients with H1N1-induced severe respiratory failure. Eur J Anaesthesiol. 2017;34(2):98–103.
83. Mikkelsen ME, et al. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab. 2000;279(6):E1242–8.
84. Wang L, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35(7):1732–7.
85. Masuda S, et al. A novel site of erythropoietin production Oxigen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269(30):19488–93.
86. Marchesi C, Paradis P, Schiffin ER. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2006;29(7):367–74.
87. Chavez JC, et al. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci. 2006;26(37):9471–81.
88. Robba C, et al. Extracranial complications after traumatic brain injury: targeting the brain and the body. Curr Opin Crit Care. 2020;26(2):137–46.
89. Robba C, et al. Mechanical ventilation in patients with acute ischaemic stroke: from pathophysiology to clinical practice. Crit Care. 2019;23(1):388.
90. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med. 1998;157(1):294–323.
91. Asehnoune K, et al. A multi-faceted strategy to reduce ventilation-associated mortality in brain-injured patients the BI-VILI project: a nationwide quality improvement project. Intensive Care Med. 2017;43(7):957–70.
92. Turon M, et al. Mechanisms involved in brain dysfunction in mechanically ventilated critically ill patients: implications and therapeutic. Ann Transl Med. 2018;6(2):30.
93. Burger D, et al. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995;96(1):38–41.
94. Tsai PT, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26(4):1269–74.
95. Wang H, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004;10(11):1216–21.
96. Digiacogliu M, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA. 1995;92(9):3717–20.
97. Marti HH, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci. 1996;8(4):666–76.
98. Morishita E, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76(1):105–16.
99. Bernaudin M, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia. 2000;30(3):271–8.
100. Riech S, et al. The pattern of brain microhemorrhages after severe lung injury resembles the one seen in high-altitude cerebral edema. Crit Care Med. 2015;43(9):e386–9.
101. Abdul Rashid AM, Bahari N, Md Noh MSF. Pediatric critical illness associated mortality in brain-injured patients the BI-VILI project: a nationwide quality improvement project. Intensive Care Med. 2019;45(7):957–70.
102. Marchesi C, Paradis P, Schiffin ER. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2006;29(7):367–74.
103. Chavez JC, et al. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci. 2006;26(37):9471–81.
104. Robba C, et al. Extracranial complications after traumatic brain injury: targeting the brain and the body. Curr Opin Crit Care. 2020;26(2):137–46.
105. Robba C, et al. Mechanical ventilation in patients with acute ischaemic stroke: from pathophysiology to clinical practice. Crit Care. 2019;23(1):388.
106. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med. 1998;157(1):294–323.
107. Asehnoune K, et al. A multi-faceted strategy to reduce ventilation-associated mortality in brain-injured patients the BI-VILI project: a nationwide quality improvement project. Intensive Care Med. 2017;43(7):957–70.
108. Turon M, et al. Mechanisms involved in brain dysfunction in mechanically ventilated critically ill patients: implications and therapeutic. Ann Transl Med. 2018;6(2):30.
109. Bassi TG, et al. Brain injury after 50 h of lung-protective mechanical ventilation in a preclinical model. Sci Rep. 2021;11(1):5105.
110. Alsop DC, et al. The role of neuroimaging in elucidating delirium pathophysiology. J Gerontol A Biol Sci Med Sci. 2006;61(12):1287–93.
111. Morandi A, et al. Tools to detect delirium superimposed on dementia: a systematic review. J Am Geriatr Soc. 2012;60(11):2005–13.
112. Gonzalez-Lopez A, et al. Mechanical ventilation triggers hippocampal apoptosis by vagal and dopaminergic pathways. Am J Respir Crit Care Med. 2013;188(6):693–702.
113. Chen T, et al. Toll-like receptor 4 knockout ameliorates neuroinflammation due to lung-brain interaction in mechanically ventilated mice. Brain Behav Immun. 2016;56:42–55.
114. Lopez-Aguilar J, et al. Hippocampal damage during mechanical ventilation in Tendelenburg position: a secondary analysis of an experimental study on the prevention of ventilator-associated pneumonia. Shock. 2019;52(1):75–82.
115. Xu X, et al. Perioperative neurocognitive dysfunction: thinking from the gut? Aging (Albany NY). 2020;12(15):15797–817.
116. Oddo M, Citerio G. ARDS in the brain-injured patient: what’s different? Intensive Care Med. 2016;42(5):790–3.
117. Petridis AK, et al. The effect of lung-protective permissive hypercapnia in intracerebral pressure in patients with subarachnoid
118. Chikhani M, et al. High PEEP in acute respiratory distress syndrome: quantitative evaluation between improved arterial oxygenation and decreased oxygen delivery. Br J Anaesth. 2016;117(6):650–8.

119. Georgiadis D, et al. Influence of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure in patients with acute stroke. Stroke. 2001;32(9):2088–92.

120. Mascia L. Acute lung injury in patients with severe brain injury: a double hit model. Neu rocrit Care. 2009;11(3):417–26.

121. Herridge MS, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293–304.

122. Antonelli M, et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med. 2007;35(1):18–25.

123. Walkey AJ, Wiener RS. Use of noninvasive ventilation in patients with acute respiratory failure, 2000–2009: a population-based study. Ann Am Thorac Soc. 2013;10(1):10–7.

124. Bellani G, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome insights from the LUNG SAFE study. Am J Respir Crit Care Med. 2017;195(1):67–77.

125. Rana S, et al. Failure of non-invasive ventilation in patients with acute lung injury: observational cohort study. Crit Care. 2006;10(3):R79.

126. Agarwal R, Aggarwal AN, Gupta D. Role of noninvasive ventilation in acute lung injury/acute respiratory distress syndrome: a proportion meta-analysis. Respir Care. 2010;55(12):1653–60.

127. Rochwerg B, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017. https://doi.org/10.1183/13993003.02426-2016.

128. Weillard-Baron A, et al. Experts’ opinion on management of hemodynamics in ARDS patients: focus on the effects of mechanical ventilation. Intensive Care Med. 2016;42(5):739–49.

129. Cortes-Puentes GA, Deckler RA, Marini JJ. Physiology-guided management of hemodynamics in acute respiratory distress syndrome. Ann Transl Med. 2018;6(18):353.

130. Mahmood SS, Pinsky MR. Heart-lung interactions during mechanical ventilation: the basics. Ann Transl Med. 2018;6(18):349.

131. Phillips AA, et al. Neurovascular coupling in humans: Physiology, methodological advances and clinical implications. J Cereb Blood Flow Metab. 2016;36(4):647–64.

132. Willie CK, Smith KJ. Fueling the exercising brain: a regulatory quagmire for lactate metabolism. J Physiol. 2011;589(Pt 4):779–80.

133. Taccone FS, et al. Cerebral autoregulation is influenced by carbon dioxide levels in patients with septic shock. Neurocrit Care. 2010;12(1):35–42.

134. Taccone FS, et al. Cerebral microcirculation is impaired during sepsis: an experimental study. Crit Care. 2010;14(4):R140.

135. Havakuk O, et al. Heart Failure-Induced Brain Injury. J Am Coll Cardiol. 2017;69(12):1609–16.

136. Claassen J, et al. Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. Physiol Rev. 2021;101(4):1487–559.

137. Czosnyka M, et al. Cerebral autoregulation following head injury. J Neurosurg. 2001;95(5):756–63.

138. Paulson OB, et al. Cerebral blood flow in patients with congestive heart failure treated with captopril. Am J Med. 1984;76(5B):91–5.

139. Jefferson AL, et al. Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol. 2011;108(9):1346–51.

140. Skelly DT, et al. A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1beta, [corrected] TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS ONE. 2013;8(7):e69123.

141. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis. Neurobiol Aging. 2000;21(2):331–42.

142. Sharshar T, et al. The neuropathology of septic shock. Brain Pathol. 2004;14(1):21–33.

143. Librizzi L, et al. Cerebrovascular heterogeneity and neuronal excitability. Neurosci Lett. 2018;667:75–83.

144. Wilhelm I, et al. Heterogeneity of the blood-brain barrier. Tissue Barriers. 2016;4(1):e1143544.